Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Journal of Oncology

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO.27.5.1247PMID 16211219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.

  2005cited by this paper
• A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.

  2005cited by this paper
• Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol

  2004cited by this paper
• Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells

  2004cited by this paper
• Induction of Thyroid Cancer Cell Apoptosis by a Novel Nuclear Factor κB Inhibitor, Dehydroxymethylepoxyquinomicin

  2004cited by this paper
• Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas

  2004cited by this paper
• Mechanism of taxol‐induced apoptosis in human SKOV3 ovarian carcinoma cells

  2004cited by this paper
• Mitochondria‐mediated caspase‐independent apoptosis induced by cadmium in normal human lung cells

  2003cited by this paper
• Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.

  2003cited by this paper
• PKCμ prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells

  2003cited by this paper
• Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.

  2003cited by this paper
• Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.

  2002cited by this paper
• Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death.

  2002cited by this paper
• Molecular design and biological activities of NF-kappaB inhibitors.

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin

  2002cited by this paper
• Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization.

  2002cited by this paper
• Cancer gene therapy using a survivin mutant adenovirus.

  2001cited by this paper
• High constitutive level of NF-κB is crucial for viability of adenocarcinoma cells

  2001cited by this paper
• Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death

  2001cited by this paper
• A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death.

  2001cited by this paper
• Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.

  2000cited by this paper
• The IAP family: endogenous caspase inhibitors with multiple biological activities

  2000cited by this paper
• The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

  2000cited by this paper
• Two Distinct Pathways Leading to Nuclear Apoptosis

  2000cited by this paper
• tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c.

  2000cited by this paper
• Mitochondrio‐nuclear translocation of AIF in apoptosis and necrosis

  2000cited by this paper
• Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c

  2000cited by this paper
• Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.

  2000cited by this paper
• Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C.

  2000cited by this paper
• Akt Suppresses Apoptosis by Stimulating the Transactivation Potential of the RelA/p65 Subunit of NF-κB

  2000cited by this paper
• Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex.

  2000cited by this paper
• The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies.

  1999cited by this paper
• Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death*

  1999cited by this paper
• The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

  1999cited by this paper
• TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells.

  1999cited by this paper
• IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

  1998cited by this paper
• Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.

  1998cited by this paper
• Inhibition of death receptor signals by cellular FLIP

  1997cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis.

  1997cited by this paper
• Molecular Ordering of Apoptotic Mammalian CED-3/ICE-like Proteases*

  1996cited by this paper
• Rel/NF-kappaB/IkappaB proteins and cancer.

  1996cited by this paper
• FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.

  1996cited by this paper
• Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor.

  1995cited by this paper
• Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo

  1995cited by this paper
• A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

  1991cited by this paper
• Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

  1989cited by this paper

• Intravenous Administration of Dehydroxymethylepoxyquinomicin With Polymer Enhances the Inhibition of Pancreatic Carcinoma Growth in Mice

  2021cites this paper
• NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells

  2017cites this paper
• Administration of IκB‐kinase inhibitor PS1145 enhances apoptosis in DMBA‐induced tumor in male Wistar rats

  2015cites this paper
• A nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates GVHD in allogeneic bone marrow transplantation.

  2015cites this paper
• Inhibition of NF-κB by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ-Radiation Cytotoxicity in Glioblastoma Cells

  2013cites this paper
• Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer

  2012cites this paper
• Inhibition of nuclear factor‐kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion

  2011cites this paper
• Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.

  2011cites this paper
• Dehydroxymethylepoxyquinomicin (DHMEQ) can suppress tumour necrosis factor‐α production in lipopolysaccharide‐injected mice, resulting in rescuing mice from death in vivo

  2011cites this paper
• Transient inhibition of NF‐κB by DHMEQ induces cell death of primary effusion lymphoma without HHV‐8 reactivation

  2009cites this paper
• Direct Rel/NF-κB inhibitors: structural basis for mechanism of action.

  2009cites this paper
• Special Topic: NF-κB, Immunity and Cancer NF-κB Signaling Pathway and Its Therapeutic Implications in Human Diseases

  2008cites this paper
• Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues.

  2008cites this paper
• NF-kappaB: a potential target for cancer chemoprevention and therapy.

  2008cites this paper
• A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry.

  2008cites this paper
• Inactivation of NF-κB

  2008cites this paper
• Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.

  2007cites this paper
• Satoh 2_11

  2006cites this paper
• Inhibition of tumor growth by NF-kappaB inhibitors.

  2006cites this paper
• Inhibition of tumor growth by NF‐κB inhibitors

  2006cites this paper
• Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.

  2006cites this paper
• Survivin associates with cell proliferation in renal cancer cells: Regulation of survivin expression by insulin-like growth factor-1, interferon-γ and a novel NF-κB inhibitor

  2006cites this paper